A Multicenter, Open-Label Long-Term Safety Study of Rimegepant for the Acute Treatment of Migraine
This multicenter, long-term, open-label safety study showed that Rimegepant 75 mg up to once per day as EOD + PRN for 12 weeks or PRN for up to 52 weeks was safe and well tolerated. No signal of hepatotoxicity, potential drug abuse, or medication-overuse headache was identified. Full Access: QMXD
Flu and MI Risk: A Sixfold Increase, Higher if No CVD History
This observational, self-controlled, case-series study showed the link between influenza infection and a rise in short-term risk for acute myocardial infarction (MI). The risk appears to be particularly elevated in individuals with no prior diagnosis of coronary artery disease. Full Access: Medscape
Cannabis, Tobacco Use, and COVID-19 Outcomes
This retrospective cohort study showed cannabis use may be an independent risk factor for COVID-19–related complications, even after considering cigarette smoking, vaccination status, comorbidities, and other risk factors. Full Access: JAMA
Sepsis Procedures and Training Now Required for UC Centers in Maryland
Lochlin’s Law (named after a child who died of sepsis after a case of influenza) in Maryland requires hospitals and Urgent Care centers to develop evidence-based protocols and education for the early recognition and treatment of sepsis. Full Access: JUCM
